KMT2A and cancer: MLL mutations were identified among various cancers and widespread shortening H3K4me3 peaks at tumor suppressor genes might contribute to tumor initiation (Zhao et al., 2021; Chen et al., 2015), and H3K27me3 could modulate chemotherapy tolerance in triple-negative breast cancer (TNBC) (Marsolier et al., 2022).